AgeneBio is developing therapies for people who have Amnestic Mild Cognitive Impairment (aMCI) and Alzheimer's disease (AD).
The company has a new clinical strategy to help address the therapeutic needs of the growing population of aMCI and AD patients.
Products under development are aimed at improving memory and preventing progression to AD.
AgeneBio's first potential product, a currently approved and reformulated CNS medication, will seek expedited registration. A Proof of Concept clinical trial evaluating this medication commenced in 2009.
The company has a well developed and diverse IP portfolio, with a strong research foundation based on the work of the founder, Dr. Michela Gallagher, a global leader in the field of neurocognitive ageing for more than 20 years.
The SAB and management teams are industry veterans with significant experience developing and commercializing CNS drugs!